DDAVP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DDAVP (DDAVP).
Synthetic analog of vasopressin; primarily activates V2 receptors in renal collecting ducts, increasing water reabsorption and concentrating urine.
| Metabolism | Not significantly metabolized; primarily renal excretion. |
| Excretion | Primarily renal (unchanged drug); >90% eliminated by kidneys. |
| Half-life | Terminal elimination half-life: 2-3 hours (intravenous); 3.4-4.4 hours (oral); clinical context: antidiuretic effect persists longer (6-20 hours) due to receptor binding. |
| Protein binding | 50%; binding proteins: predominantly albumin. |
| Volume of Distribution | 0.3 L/kg; indicates distribution primarily in extracellular fluid. |
| Bioavailability | Intranasal: 10-20%; oral: 0.1-0.5% (sublingual tablets); subcutaneous: 100% (absolute bioavailability). |
| Onset of Action | Intranasal: 15-30 minutes; intravenous: 15-30 minutes; oral: 30-60 minutes; subcutaneous: 15-30 minutes. |
| Duration of Action | Dose-dependent; antidiuretic effect: 6-20 hours for intranasal, 6-12 hours for intravenous, 8-12 hours for oral; hemostatic effect: 4-8 hours for intravenous or high-dose intranasal. |
Central diabetes insipidus: 0.1-0.4 mg orally every 12-24 hours or 0.5-1 mcg subcutaneously/intranasally every 12-24 hours. Nocturnal enuresis: 0.2-0.4 mg orally at bedtime. Hemophilia A/von Willebrand disease: 0.3 mcg/kg intravenous over 15-30 minutes or 300 mcg subcutaneously or 150 mcg intranasally (for >50 kg).
| Dosage form | TABLET |
| Renal impairment | Not recommended if GFR <50 mL/min; use with caution if GFR 50-90 mL/min. No standard dose adjustment available; risk of water intoxication increases in renal impairment. |
| Liver impairment | No dose adjustment recommended based on Child-Pugh class. Use with caution in severe hepatic impairment due to potential for fluid overload. |
| Pediatric use | Central diabetes insipidus: 0.05-0.1 mg orally every 12-24 hours (titrate). Nocturnal enuresis: 0.2-0.4 mg orally at bedtime (age ≥6 years). Hemophilia A/vWD: 0.3 mcg/kg intravenous over 15-30 minutes; intranasal dose: 150 mcg (if ≤50 kg) or 300 mcg (if >50 kg); subcutaneous: 0.3 mcg/kg. |
| Geriatric use | Start at lower end of dosing range (e.g., 0.1 mg orally once daily). Monitor serum sodium and fluid balance closely due to increased risk of hyponatremia and renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DDAVP (DDAVP).
| Breastfeeding | Excreted in breast milk in low amounts (M/P ratio unknown). No adverse effects reported in infants; consider risk-benefit for maternal indication. |
| Teratogenic Risk | Category B: No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; risk cannot be excluded. Second and third trimester: No reported fetal harm, but avoid in preeclampsia due to antidiuretic effect. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to desmopressin or components","Moderate to severe renal impairment (CrCl < 50 mL/min)","Type IIB or platelet-type von Willebrand disease","Severe hyponatremia"]
| Precautions | ["Risk of hyponatremia","Fluid intake restriction to avoid water intoxication","Seizures in severe hyponatremia","Cardiovascular disease caution (hypertension, coronary artery disease)"] |
Loading safety data…
| Monitor serum sodium, urine output, and blood pressure. In pregnancy, assess for uterine contractions (oxytocic effect at high doses) and fetal heart rate if used for diabetes insipidus. |
| Fertility Effects | No known adverse effects on fertility. May be used in women with central diabetes insipidus without impairing reproductive function. |